| Bioactivity | EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively[1]. | ||||||||||||
| Name | EMT inhibitor-2 | ||||||||||||
| CAS | 2232228-60-1 | ||||||||||||
| Formula | C24H26N2O8 | ||||||||||||
| Molar Mass | 470.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Youn, Byung Soo, et al. Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis. US10370364. |
EMT inhibitor-2
CAS: 2232228-60-1 F: C24H26N2O8 W: 470.47
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and T
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.